Viewing data from:

LEVOCETIRIZINE DIHYDROCHLORIDE

ANDA

LEVOCETIRIZINE DIHYDROCHLORIDE | A090199 | TEVA PHARMACEUTICALS USA

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Levocetirizine Dihydrochloride (2023)

Total Spending

$38.0M

Total Claims

2,093,762

Beneficiaries

642,854

Avg Cost/Unit

$0.32

Spending Trend

$23.7M(2019)→$30.9M(2020)→$33.7M(2021)→$37.3M(2022)→$38.0M(2023)

YoY Change:-6.0%

5yr CAGR:+0.8%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain11 active DMFs2 inactive

11 active API suppliers hold Drug Master Files for this ingredient.

CIPLA LTDLEVOCETIRIZINE DIHYDROCHLORIDE USP

DMF 201732007

GLOCHEM INDUSTRIES PRIVATE LTDLEVOCETIRIZINE DIHYDROCHLORIDE USP

DMF 211102007

SUN PHARMACEUTICAL INDUSTRIES LTDLEVOCETIRIZINE DIHYDROCHLORIDE

DMF 212142008

COHANCE LIFESCIENCES LTDLEVOCETIRIZINE DIHYDROCHLORIDE USP

DMF 214172008

SYMED LABS LTDLEVOCETIRIZINE DIHYDROCHLORIDE

DMF 222862008

ALIVUS LIFE SCIENCES LTDLEVOCETIRIZINE DIHYDROCHLORIDE USP

DMF 226772009

GRANULES INDIA LTDLEVOCETIRIZINE DIHYDROCHLORIDE USP

DMF 228982009

TARO PHARMACEUTICAL INDUSTRIES LTDLEVOCETIRIZINE DIHYDROCHLORIDE USP

DMF 243432010

JUBILANT PHARMOVA LTDLEVOCETIRIZINE DIHYDROCHLORIDE USP

DMF 252792012

CHROMO LABORATORIES INDIA PRIVATE LTDLEVOCETIRIZINE DIHYDROCHLORIDE USP

DMF 332192019

METROCHEM API PRIVATE LTDLEVOCETIRIZINE DIHYDROCHLORIDE USP

DMF 347312020

WAVELENGTH ENTERPRISES LTDInactiveLEVOCETIRIZINE DIHYDROCHLORIDE

DMF 241612010

SYNTHON BVInactiveLEVOCETIRIZINE DIHYDROCHLORIDE

DMF 245612011

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 5MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Aug 22, 2011

No patent or exclusivity listings for this strength.